Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26830864 | 1.00 | MAPT (0.51) | MAPTKDM4EALDH1A1KMT2ABCHE | |
| SCHEMBL1754976 | 0.90 | MAPT (0.56) | MAPTKDM4EALDH1A1KMT2AHCAR3 | |
| SCHEMBL14937157 | 0.88 | MAPT (0.59) | MAPTKDM4EALDH1A1KMT2AHCAR3 | |
| SCHEMBL21751573 | 0.86 | MAPT (0.54) | MAPTKMT2ABCHECNR2HCAR3 | |
| SCHEMBL21751643 | 0.86 | MAPT (0.54) | MAPTKMT2ABCHECNR2HCAR3 | |
| SCHEMBL21751704 | 0.86 | MAPT (0.54) | MAPTKMT2ABCHECNR2HCAR3 | |
| SCHEMBL21070371 | 0.86 | NPC1 (0.51) | MAPTALDH1A1KMT2ABCHECNR2 | |
| SCHEMBL29612659 | 0.86 | NPC1 (0.51) | MAPTALDH1A1KMT2ABCHECNR2 | |
| SCHEMBL21553566 | 0.85 | MAPT (0.56) | MAPTKDM4EALDH1A1KMT2AHCAR3 | |
| SCHEMBL22162663 | 0.85 | MAPT (0.56) | MAPTKDM4EALDH1A1KMT2AHCAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250339541-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250213699-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2025-07-03 | — | — | US | disclosed |
| US-12290568-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | AVILAR THERAPEUTICS, INC. (US) | 2025-05-06 | — | — | US | disclosed |
| US-12280116-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | AVILAR THERAPEUTICS, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| US-20240424108-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-12-26 | — | — | US | disclosed |
| US-12128106-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | AVILAR THERAPEUTICS, INC. (US) | 2024-10-29 | — | — | US | disclosed |
| US-20240307546-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-09-19 | — | — | US | disclosed |
| US-12076408-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | AVILAR THERAPEUTICS, INC. (US) | 2024-09-03 | — | — | US | disclosed |
| US-20240245785-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-07-25 | — | — | US | disclosed |
| US-20240072809-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | US | disclosed |
| US-11819551-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | AVILAR THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-20230097256-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2023-03-30 | — | — | US | disclosed |
| EP-4097138-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | Avila Therapeutics, Inc. (US) | 2022-12-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11819551-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | ASGR1, ENGASE, FCGR2A | MAPT 4521/4885KDM4E 4460/4885ALDH1A1 3319/4885 |
| US-20250339541-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | ASGR1, ENGASE, FCGR2A | MAPT 4521/4885KDM4E 4460/4885ALDH1A1 3319/4885 |
| US-20240424108-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | ASGR1, ENGASE, FCGR2A | MAPT 4521/4885KDM4E 4460/4885ALDH1A1 3319/4885 |
| US-20250213699-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | ASGR1, ENGASE, FCGR2A | MAPT 4521/4885KDM4E 4460/4885ALDH1A1 3319/4885 |
| US-20230097256-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | ASGR1, ENGASE, FCGR2A | MAPT 4521/4885KDM4E 4460/4885ALDH1A1 3319/4885 |
| US-12076408-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | ASGR1, ENGASE, FCGR2A | MAPT 4521/4885KDM4E 4460/4885ALDH1A1 3319/4885 |
| US-12128106-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | ASGR1, ENGASE, FCGR2A | MAPT 4521/4885KDM4E 4460/4885ALDH1A1 3319/4885 |
| US-12290568-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | ASGR1, ENGASE, FCGR2A | MAPT 4521/4885KDM4E 4460/4885ALDH1A1 3319/4885 |
| US-12280116-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | ASGR1, ENGASE, FCGR2A | MAPT 4521/4885KDM4E 4460/4885ALDH1A1 3319/4885 |
| US-20240245785-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | ASGR1, ENGASE, FCGR2A | MAPT 4521/4885KDM4E 4460/4885ALDH1A1 3319/4885 |
| US-20240307546-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | ASGR1, ENGASE, FCGR2A | MAPT 4521/4885KDM4E 4460/4885ALDH1A1 3319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.